Skip to main content
Journal cover image

Analysis of dermatologic events in patients with cancer treated with lapatinib.

Publication ,  Journal Article
Lacouture, ME; Laabs, SM; Koehler, M; Sweetman, RW; Preston, AJ; Di Leo, A; Gomez, HL; Salazar, VM; Byrne, JA; Koch, KM; Blackwell, KL
Published in: Breast Cancer Res Treat
April 2009

PURPOSE: Dermatologic events (DEs) in patients with cancer treated with lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR [ErbB1]) and HER2 (ErbB2), were characterized. PATIENTS AND METHODS: Nine clinical trials of metastatic cancer were included in this analysis. Lapatinib was administered at doses ranging from 1000 to 1500 mg/day as monotherapy (n=928) or in combination with paclitaxel or capecitabine (n=491). Patients not treated with lapatinib comprised the control group. Dermatologic events included hand-foot syndrome, rash, hair disorder, dry skin, pruritus/urticaria, skin disorder, skin infection, and nail disorder; DEs were characterized based on type, time to onset, severity, duration, and required interventions. RESULTS: Fifty-eight percent of patients treated with lapatinib monotherapy, 74% treated with lapatinib plus paclitaxel or capecitabine, and 53% in the control group developed DEs. Among patients receiving lapatinib monotherapy, 55% experienced grade 1/2 DEs, 3% had grade 3 DEs, and no grade 4 DEs were observed. The most common DE was rash (43%); all other events occurred in

Duke Scholars

Published In

Breast Cancer Res Treat

DOI

EISSN

1573-7217

Publication Date

April 2009

Volume

114

Issue

3

Start / End Page

485 / 493

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Skin Diseases
  • Quinazolines
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasms
  • Middle Aged
  • Male
  • Lapatinib
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lacouture, M. E., Laabs, S. M., Koehler, M., Sweetman, R. W., Preston, A. J., Di Leo, A., … Blackwell, K. L. (2009). Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat, 114(3), 485–493. https://doi.org/10.1007/s10549-008-0020-7
Lacouture, M. E., S. M. Laabs, M. Koehler, R. W. Sweetman, A. J. Preston, A. Di Leo, H. L. Gomez, et al. “Analysis of dermatologic events in patients with cancer treated with lapatinib.Breast Cancer Res Treat 114, no. 3 (April 2009): 485–93. https://doi.org/10.1007/s10549-008-0020-7.
Lacouture ME, Laabs SM, Koehler M, Sweetman RW, Preston AJ, Di Leo A, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2009 Apr;114(3):485–93.
Lacouture, M. E., et al. “Analysis of dermatologic events in patients with cancer treated with lapatinib.Breast Cancer Res Treat, vol. 114, no. 3, Apr. 2009, pp. 485–93. Pubmed, doi:10.1007/s10549-008-0020-7.
Lacouture ME, Laabs SM, Koehler M, Sweetman RW, Preston AJ, Di Leo A, Gomez HL, Salazar VM, Byrne JA, Koch KM, Blackwell KL. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2009 Apr;114(3):485–493.
Journal cover image

Published In

Breast Cancer Res Treat

DOI

EISSN

1573-7217

Publication Date

April 2009

Volume

114

Issue

3

Start / End Page

485 / 493

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Skin Diseases
  • Quinazolines
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasms
  • Middle Aged
  • Male
  • Lapatinib
  • Humans